The Lancet journals: Papers at ESC Congress 2019

The following papers will be presented at the ESC Congress 2019, organised by the European Society of Cardiology in Paris and published simultaneously in either

The Lancet

or

The Lancet Global Health

journals. All papers are under embargo until the stated time. Contact details for corresponding authors are provided in the Articles and linked Comments. Funding information is listed on the first page of each Article.

Embargo: 13.30hrs [UK time] / 14.30hrs [Paris time] / 8.30 am [New York time] on Sunday 1st September 2019

The Lancet:

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Once the embargo lifts, please use this link as the one above will be deactivated:

http://www.

thelancet.

com/

journals/

lancet/

article/

PIIS0140-6736

(19)31887-2/fulltext

Embargo: 7.30hrs [UK time] / 8.30hrs [Paris time] / 2.30 am [New York time] on Monday 2nd September 2019

The Lancet:

Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study

Once the embargo lifts, please use this link as the one above will be deactivated:

http://www.

thelancet.

com/

journals/

lancet/

article/

PIIS0140-6736

(19)31996-8/fulltext

Embargo: 7.30hrs [UK time] / 8.30hrs [Paris time] / 2.30 am [New York time] on Monday 2nd September 2019

The Lancet:

Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial

Once the embargo lifts, please use this link as the one above will be deactivated:

http://www.

thelancet.

com/

journals/

lancet/

article/

PIIS0140-6736

(19)31877-X/fulltext

Embargo: 10.00hrs [UK time] / 11.00hrs [Paris time] / 5.00am [New York time] on Monday 2nd September 2019 –

The Lancet:

A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial

**Full press release to be distributed around midday New York time on Thursday 29th August**

Once the embargo lifts, please use this link as the one above will be deactivated:

http://www.

thelancet.

com/

journals/

lancet/

article/

PIIS0140-6736

(19)31949-X/fulltext

Embargo: 14.30hrs [UK time] / 15.30hrs [Paris time] / 9.30am [New York time] on Monday 2nd September 2019

The Lancet Global Health:

World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions

Once the embargo lifts, please use this link as the one above will be deactivated:

http://www.

thelancet.

com/

journals/

langlo/

article/

PIIS2214-109X

(19)30318-3/fulltext

Embargo: 15.40hrs [UK time] / 16.40hrs [Paris time] / 10.40am [New York time] on Monday 2nd September 2019

The Lancet:

Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease:

10-year follow-up of the multicentre randomised controlled SYNTAX trial

Once the embargo lifts, please use this link as the one above will be deactivated:

http://www.

thelancet.

com/

journals/

lancet/

article/

PIIS0140-6736

(19)31997-X/fulltext

Embargo: 10.00hrs [UK time] / 11.00hrs [Paris time] / 5.00am [New York time] on Tuesday 3rd September 2019

The Lancet:

Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study

**Full press release and finalised papers to be distributed around midday New York time on Friday 30th August**

Embargo: 10.00hrs [UK time] / 11.00hrs [Paris time] / 5.00am [New York time] on Tuesday 3rd September 2019

The Lancet:

Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study

**Full press release and finalised papers to be distributed around midday New York time on Friday 30th August**

Embargo: 15.40hrs [UK time] / 16.40hrs [Paris time] / 10.40am [New York time] on Tuesday 3rd September 2019

The Lancet:

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

Once the embargo lifts, please use this link as the one above will be deactivated:

http://www.

thelancet.

com/

journals/

lancet/

article/

PIIS0140-6736

(19)31872-0/fulltext

###